Inspire Medical price target lowered to $200 from $220 at Morgan Stanley

Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Inspire Medical (INSP) to $200 from $220 and keeps an Overweight rating on the shares. The firm thinks Inspire’s Q1 report was “better than the buyside had expected,” with good outperformance at both the top and bottom line. The Inspire V full launch was confirmed for May, helping to address concerns from some investors on a rollout being pushed to far later in the year, the analyst added.